Cost-effectiveness analysis estimates clinical and economic benefits of PCV20 for pneumococcal disease in children, suggesting significant advantages over lower-valent vaccines.
Implementing PCV20 into the Slovakian pediatric NIP is projected to yield the most significant clinical and economic benefits compared to the two lower-valent PCVs, due to its more extensive protection against a broader range of pneumococcal serotypes. Despite an additional cost of dose and visit, PCV20 was estimated to be cost-effective at the Slovak WTP threshold versus other SoC options over a 10-year time horizon.
No takes yet. Share an insight, caveat, or question.
Wannaadisai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: